These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34593263)

  • 21. Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC.
    Ross-Macdonald P; Walsh AM; Chasalow SD; Ammar R; Papillon-Cavanagh S; Szabo PM; Choueiri TK; Sznol M; Wind-Rotolo M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658305
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
    Procopio G; Verzoni E; De Braud F
    Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
    [No Abstract]   [Full Text] [Related]  

  • 23. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re: Ekaterina Laukhtina, Sung Ryul Shim, Keiichiro Mori, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol 2021;4:927-42: Considerations for Interpreting Data Presented in Systematic Reviews and Network Meta-analyses of Urinary Biomarker Tests.
    Chiang CH; Chiang CH; Chiang CH
    Eur Urol Oncol; 2022 Apr; 5(2):263-264. PubMed ID: 35074283
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reply to Nirmish Singla and Vitaly Margulis's Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition: Nephrectomy After Immunotherapy: The Duration of Treatment Exposure is Probably Decisive.
    Pignot G; Thiery-Vuillemin A; Walz J; Bigot P; Bensalah K; Gravis G; Barthélémy P
    Eur Urol; 2020 Aug; 78(2):e81-e82. PubMed ID: 32389444
    [No Abstract]   [Full Text] [Related]  

  • 27. Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer.
    Kuusk T; Albiges L; Escudier B; Grivas N; Haanen J; Powles T; Bex A
    Angiogenesis; 2017 May; 20(2):205-215. PubMed ID: 28401381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 29. A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.
    Nunes-Xavier CE; Angulo JC; Pulido R; López JI
    Curr Urol Rep; 2019 Jan; 20(1):1. PubMed ID: 30645700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
    Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-dose corticosteroid use and risk of hospitalization for infection in patients treated with immune checkpoint inhibitors--A nationwide register-based cohort study.
    Sørup S; Darvalics B; Russo L; Oksen D; Lamy FX; Verpillat P; Aa K; Ht S; Cronin-Fenton D
    Cancer Med; 2021 Jul; 10(14):4957-4963. PubMed ID: 34105315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Programmed Death-Ligand 1 and MET Inhibition: Has Papillary Renal Cell Carcinoma MET Its Match?
    Brown JT; Nazha B; Bilen MA
    J Clin Oncol; 2023 May; 41(14):2467-2470. PubMed ID: 36809042
    [No Abstract]   [Full Text] [Related]  

  • 33. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.
    de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L
    Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitoris necessary in the treatment of advanced or metastatic renal cell carcinoma.
    Sun L; Zhang L; Yu J; Zhou Y; Shi C; Wasan HS; Ruan S; Huang D
    Med Oncol; 2020 Feb; 37(2):15. PubMed ID: 32008152
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
    Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
    Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atezolizumab for the treatment of renal cell carcinoma.
    Lafon M; Domblides C; Daste A; Sionneau B; Ravaud A; Bernhard JC; Gross-Goupil M
    Expert Opin Biol Ther; 2020 Jul; 20(7):679-686. PubMed ID: 32245328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: a meta-analysis.
    Rizzo A; Mollica V; Santoni M; Rosellini M; Marchetti A; Ricci AD; Grilli G; Greco A; Montironi R; Ardizzoni A; Massari F
    Immunotherapy; 2021 Jun; 13(9):783-793. PubMed ID: 33906376
    [No Abstract]   [Full Text] [Related]  

  • 38. Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Liu Y; Shabto JM; Carthon BC; Hitron EE; Russler GA; Caulfield S; Kissick HT; Harris WB; Kucuk O; Master VA; Bilen MA
    Oncologist; 2020 Mar; 25(3):e484-e491. PubMed ID: 32162798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comprehensive review of the role of immune checkpoint inhibitors in brain metastasis of renal cell carcinoma origin.
    Kattan J; Rassy EE; Assi T; Bakouny Z; Pavlidis N
    Crit Rev Oncol Hematol; 2018 Oct; 130():60-69. PubMed ID: 30196913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avelumab and axitinib combination therapy for the treatment of advanced renal cell carcinoma.
    Soleimani M; Nappi L; Kollmannsberger C
    Future Oncol; 2020 Dec; 16(36):3021-3034. PubMed ID: 32856478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.